BreanneHitchen (Bre)


Cleveland + 1.216.586.7094

Bre Hitchen focuses her practice on the representation of health care and life sciences companies. She has represented hospitals, health systems, academic medical centers, pharmaceutical and medical device manufacturers, electronic health record developers, and other health care-related entities.

Bre has defended health care clients in investigations and litigation brought by federal agencies and qui tam whistleblowers. She also has experience advising clients on compliance strategies, as well as on a wide range of regulatory issues, such as kickbacks, billing, coding, documentation errors, HIPAA and related health information privacy rules, and potential Stark liability. Additionally, she has worked with clients engaged in a variety of transactions, including mergers, acquisitions, joint ventures, reorganizations, and other affiliations.

Bre also maintains an active pro bono practice. She participates in the Firm's Laredo Project, representing individuals in asylum proceedings, and working on the ground in Laredo, Texas, screening and counseling individuals seeking asylum in the United States.

She is a member of the American Health Law Association and the Cleveland Metropolitan Bar Association.


  • MEDHOST obtains dismissal of qui tam action relating to alleged false claims under HITECH ActJones Day obtained a dismissal on behalf of MEDHOST, Inc. (a developer of electronic health record ("EHR") software) in a qui tam False Claims Act action.
  • Inpatient rehabilitation facility successfully resolves overpaymentJones Day advised an inpatient rehabilitation facility ("IRF") in its successful resolution of a potential overpayment arising from IRF clinical documentation.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Digital health companies, specialty hospitals, and health systems maintain compliance with multistate requirements through 50-state surveyJones Day is representing digital health companies, specialty hospitals, and health systems in maintaining compliance with multistate requirements through a regularly updated, extensive 50-state survey on state laws and regulations applicable to telehealth activities of physicians and other health care professionals including licensing, establishing patient relationships, provider-to-provider consulting, supervision and delegation among providers, and prescribing and treatment standards.
  • Air Medical Group Holdings acquires Seven Bar Aviation, LLCJones Day advised Air Medical Group Holdings (AMGH) in its acquisition of Seven Bar Aviation, LLC (SBA), a privately-held air medical operator offering fixed and rotor wing services to a broad array of leading healthcare organizations throughout the nation.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Blue Point Capital Partners recapitalizes TAS Environmental ServicesJones Day represented Blue Point Capital Partners in connection with the recapitalization and related financing of TAS Environmental Services, a leading regional environmental services company.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.